Safety of anti-TNF agents in patients with compensated cirrhosis: a case-control study

1. Elliott, MJ, Maini, RN, Feldmann, M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–1110.
Google Scholar | Crossref | Medline | ISI2. Targan, SR, Hanauer, SB, van Deventer, SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 1029–1035.
Google Scholar | Crossref | Medline | ISI3. Iyer, S, Yamauchi, P, Lowe, NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002; 146: 118–121.
Google Scholar | Crossref | Medline | ISI4. Mariette, X, Matucci-Cerinic, M, Pavelka, K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895–1904.
Google Scholar | Crossref | Medline | ISI5. Amari, W, Zeringue, AL, McDonald, JR, et al. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology 2011; 50: 1431–1439.
Google Scholar | Crossref | Medline6. Ali, T, Kaitha, S, Mahmood, S, et al. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf 2013; 5: 79–99.
Google Scholar | Crossref | Medline7. Galloway, JB, Hyrich, KL, Mercer, LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011; 50: 124–131.
Google Scholar | Medline8. Björnsson, ES, Gunnarsson, BI, Gröndal, G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol 2015; 13: 602–608.
Google Scholar | Crossref | Medline9. Di Bisceglie, AM, Lok, AS, Martin, P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61: 703–711.
Google Scholar | Crossref | Medline10. European Association for the Study of the Liver . EASL clinical practice guidelines for the management of patients with decompensated cirrhosis [Published correction appears in J Hepatol 2018; 69: 1207]. J Hepatol 2018; 69: 406–460.
Google Scholar | Crossref | Medline11. Clària, J, Stauber, RE, Coenraad, MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 2016; 64: 1249–1264.
Google Scholar | Crossref | Medline12. Navasa, M, Follo, A, Filella, X, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998; 27: 1227–1232.
Google Scholar | Crossref | Medline | ISI13. Byl, B, Roucloux, I, Crusiaux, A, et al. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology 1993; 104: 1492–1497.
Google Scholar | Crossref | Medline14. Le Moine, O, Marchant, A, De Groote, D, et al. Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis. Hepatology 1995; 22: 1436–1439.
Google Scholar | Crossref | Medline15. McClain, CJ, Cohen, DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989; 9: 349–351.
Google Scholar | Crossref | Medline | ISI16. D’Amico, G, Garcia-Tsao, G, Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217–231.
Google Scholar | Crossref | Medline | ISI17. Bird, GL, Sheron, N, Goka, AK, et al. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917–920.
Google Scholar | Crossref | Medline18. Naveau, S, Emilie, D, Balian, A, et al. Plasma levels of soluble tumor necrosis factor receptors p55 and p75 in patients with alcoholic liver disease of increasing severity. J Hepatol 1998; 28: 778–784.
Google Scholar | Crossref | Medline19. Menon, KV, Stadheim, L, Kamath, PS, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004; 99: 255–260.
Google Scholar | Crossref | Medline | ISI20. Naveau, S, Chollet-Martin, S, Dharancy, S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390–1397.
Google Scholar | Crossref | Medline | ISI21. Boetticher, NC, Peine, CJ, Kwo, P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953–1960.
Google Scholar | Crossref | Medline | ISI22. Verhoeven, F, Weil-Verhoeven, D, Prati, C, et al. Safety of TNF inhibitors in rheumatic disease in case of NAFLD and cirrhosis. Semin Arthritis Rheum 2020; 50: 544–548.
Google Scholar | Crossref | Medline23. Dhere, T. Use of biologics in inflammatory bowel disease patients with cirrhosis. Inflamm Bowel Dis 2011; 17: E15–E16.
Google Scholar | Crossref | Medline24. Desideri, F, Pagnini, C, Marignani, M. Administration of two anti-TNFα agents in an ulcerative colitis patient with HBV-related cirrhosis. J Crohns Colitis 2015; 9: 430–431.
Google Scholar | Crossref | Medline25. Piel, S, Dissemond, J. Adalimumab therapy of psoriasis and psoriatic arthritis in a patient with cirrhosis of the liver. J Am Acad Dermatol 2008; 59(Suppl. 5): S117–S118.
Google Scholar | Crossref | Medline26. Lehnen, M, Franckson, T, Knab, J, et al. Successful infliximab therapy of psoriasis vulgaris and psoriatic arthritis in a patient with cirrhosis. Br J Dermatol 2005; 153: 212–214.
Google Scholar | Crossref | Medline27. Herrinton, LJ, Liu, L, Chen, L, et al. Association between anti-TNF-α therapy and all-cause mortality. Pharmacoepidemiol Drug Saf 2012; 21: 1311–1320.
Google Scholar | Crossref | Medline28. Jacobsson, LT, Turesson, C, Nilsson, JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 670–675.
Google Scholar | Crossref | Medline29. Foreman, MG, Mannino, DM, Moss, M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest 2003; 124: 1016–1020.
Google Scholar | Crossref | Medline | ISI30. Arvaniti, V, D’Amico, G, Fede, G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246–1256.e12565.
Google Scholar | Crossref | Medline31. Singh, JA, Cameron, C, Noorbaloochi, S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015; 386: 258–265.
Google Scholar | Crossref | Medline32. Shah, ED, Farida, JP, Siegel, CA, et al. Risk for overall infection with anti-TNF and anti-integrin agents used in IBD: a systematic review and meta-analysis. Inflamm Bowel Dis 2017; 23: 570–577.
Google Scholar | Crossref | Medline33. El-Serag, HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118–1127.
Google Scholar | Crossref | Medline | ISI34. Sorensen, HT, Friis, S, Olsen, JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998; 28: 921–925.
Google Scholar | Crossref | Medline35. Kalaitzakis, E, Gunnarsdottir, SA, Josefsson, A, et al. Increased risk for malignant neoplasms among patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9: 168–174.
Google Scholar | Crossref | Medline36. Askling, J, Fored, CM, Brandt, L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421–1426.
Google Scholar | Crossref | Medline37. Mercer, LK, Lunt, M, Low, AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2015; 74: 1087–1093.
Google Scholar | Crossref | Medline38. Di Nuzzo, S, Boccaletti, V, Fantini, C, et al. Are anti-TNF-α agents safe for treating psoriasis in hepatitis C virus patients with advanced liver disease? Case reports and review of the literature. Dermatology 2016; 232: 102–106.
Google Scholar | Crossref | Medline39. Nilsson, E, Anderson, H, Sargenti, K, et al. Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. Aliment Pharmacol Ther 2019; 49: 1421–1430.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif